State Street
ZYNE

State Street’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

State Street’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-119,741
Closed -$39K – 4645
2023
Q2 		$39K Hold
119,741
– – ﹤0.01% 4478
2023
Q1 		$51.5K Hold
119,741
– – ﹤0.01% 4494
2022
Q4 		$63.5K Hold
119,741
– – ﹤0.01% 4498
2022
Q3 		$88K Hold
119,741
– – ﹤0.01% 4508
2022
Q2 		$137K Hold
119,741
– – ﹤0.01% 4369
2022
Q1 		$245K Buy
119,741
+10,303
+9% +$24.5K ﹤0.01% 4310
2021
Q4 		$315K Hold
109,438
– – ﹤0.01% 4171
2021
Q3 		$464K Hold
109,438
– – ﹤0.01% 4007
2021
Q2 		$579K Buy
109,438
+97,838
+843% +$470K ﹤0.01% 3803
2021
Q1 		$54K Buy
+11,600
New +$52.6K ﹤0.01% 3937
2020
Q3 		– Sell
-23,250
Closed -$78K – 3875
2020
Q2 		$78K Sell
23,250
-401,475
-95% -$1.9M ﹤0.01% 3676
2020
Q1 		$1.63M Buy
424,725
+21,034
+5% +$97.7K ﹤0.01% 3140
2019
Q4 		$2.44M Buy
403,691
+19,694
+5% +$135K ﹤0.01% 3180
2019
Q3 		$2.9M Buy
383,997
+31,345
+9% +$353K ﹤0.01% 3073
2019
Q2 		$4.78M Buy
352,652
+336,414
+2,072% +$3.88M ﹤0.01% 2849
2019
Q1 		$88K Sell
16,238
-140
-0.9% -$681 ﹤0.01% 3646
2018
Q4 		$49K Sell
16,378
-510
-3% -$2.79K ﹤0.01% 3681
2018
Q3 		$137K Sell
16,888
-1,063
-6% -$8.16K ﹤0.01% 3624
2018
Q2 		$176K Sell
17,951
-165,440
-90% -$1.7M ﹤0.01% 3582
2018
Q1 		$1.59M Buy
183,391
+14,708
+9% +$159K ﹤0.01% 3240
2017
Q4 		$2.11M Buy
168,683
+18,264
+12% +$209K ﹤0.01% 3165
2017
Q3 		$1.26M Sell
150,419
-8,546
-5% -$90.4K ﹤0.01% 3331
2017
Q2 		$2.7M Buy
+158,965
New +$3.16M ﹤0.01% 3012
2016
Q2 		– Sell
-37,629
Closed -$356K – 3781
2016
Q1 		$356K Buy
37,629
+562
+2% +$4.53K ﹤0.01% 3408
2015
Q4 		$372K Buy
+37,067
New +$491K ﹤0.01% 3391

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street's ZYNE Position: Q3 2023 in Review

State Street sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 119,741 shares — an estimated $39K sold.

State Street first reported a position in ZYNE in Q4 2015 and held it in 25 quarters. The position peaked at $4.78M in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

  • State Street reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • State Street sold 119,741 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $39K.
  • State Street first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 25 quarters.
  • State Street's Zynerba Pharmaceuticals, Inc position peaked at $4.78M in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.